SCT indications and procedures are increasing worldwide. We sought to estimate the prevalence of acute respiratory failure (ARF) of any cause in hospitalized SCT patients, and assess the impact of invasive mechanical ventilation (IMV) on outcomes. We hypothesize that duration of IMV in such patients is an independent predictor of higher mortality. We performed a retrospective analysis of the largest all-payer hospitalization data set in the United States, Nationwide In-patient Sample for years [2004][2005][2006][2007][2008][2009][2010]. Of the 101 462 SCT hospitalizations, 6074 (6%) developed ARF and were the final cohort. Type of SCT with ARF included autologous 1987 (32.7%), allogeneic 3467 (57.1%) and cord blood 655 (10.8%). Duration of IMV included o96 h (17.1%) and ⩾ 96 h (41.1%). Overall in-hospital mortality (IHM) was 50.6% (3075). Predictors of IHM were IMV o96 h (odds ratio = 3.42 (2.44-4.79), P o0.0001) or IMV ⩾ 96 h (OR = 4.61 (3.17-6.70), P o 0.0001). Type of SCT, comorbid burden, gender, hospital-teaching status/bed size or insurance did not influence IHM. IMV ⩾ 96 h was associated with higher hospital charges (mean $762 515, 95% estimate 0.3991 (0.3123-0.4859), increase of $304 474, P o 0.0001) and higher length of stay (mean 61.5 days, 95% estimate 0.2198 (0.1531-0.2866), increase of 13 days, P o 0.0001). In conclusion, ARF in hospitalized SCT patients is not an uncommon occurrence and is associated with 50% mortality. Duration of IMV (⩾96 h) was an independent predictor of higher mortality rates. Hospital resource utilization was significant.
INTRODUCTION
Respiratory failure associated with the acute respiratory distress syndrome (ARDS) is an important cause of morbidity, mortality and hospital resource utilization with a considerable impact on public health. [1] [2] [3] [4] [5] Survival among mechanically ventilated patients with ARDS depends on a multitude of factors, including conditions present at the onset of respiratory failure, the development of complications and management strategies used in the intensive care unit (ICU). 6 Several studies have shown that outcomes of mechanically ventilated patients have improved over time, a finding partly related to certain patient characteristics and the widespread application of more protective ventilation strategies. [7] [8] [9] [10] In oncologic patients, acute respiratory failure (ARF) is the most common cause of ICU admission and the leading non-relapse cause of mortality following chemotherapy or BMT. [11] [12] [13] Need for mechanical ventilation is a major determinant of prognosis in oncology patients with an ICU mortality exceeding 75% for patients who have respiratory failure associated with ARDS. [14] [15] [16] [17] Approximately 25% of all BM recipients ultimately require mechanical ventilation for respiratory failure, usually within 60 days of marrow infusion. [18] [19] [20] In a large study of BM transplant patients with acute respiratory failure, invasive mechanical ventilation was associated with a poor prognosis, with only 6% of 865 surviving for more than 30 days after extubation. 19 However, available studies are limited by smaller numbers, single center experiences and/or older data.
Although stem cell transplant (BM, PB and cord blood) indications and procedures have increased in United States and worldwide in the past decade, 21 current national estimates and resource utilization of hospitalized stem cell transplant patients needing mechanical ventilation for ARF are lacking. In addition, little is known regarding how the duration of mechanical ventilation affects outcomes.
The objectives of the present study are to estimate the prevalence of ARF of any cause in hospitalized stem cell transplant patients and to assess the impact of mechanical ventilation, both noninvasive and invasive, on outcomes including in-hospital mortality and hospital resource utilization. We hypothesize that duration of invasive mechanical ventilation is an independent predictor of higher mortality rate in hospitalized stem cell transplant patients with acute respiratory failure.
MATERIALS AND METHODS

Description of Nationwide In-patient Sample
The Nationwide In-patient Sample (NIS) for the years 2004-2010 was used for the present study. The NIS is the largest all-payer in-patient database in the United States. It is a part of the Healthcare Cost and Utilization Project sponsored by the Agency for Healthcare Research and Quality. 22 The sampling frame of NIS is based on hospital location (rural or urban), hospital geographic region, bed size of hospital, teaching status and ownership/control. NIS provides discharge information on close to 40 million hospitalizations, which approximates to 97% of all hospital discharges occurring in the United States annually. A multitude of data elements including primary and secondary diagnoses, comorbidity measures, procedures performed during hospitalization, discharge status of patients, patient demographic information (including age, gender, race and insurance status), type of admission (elective or emergency/urgent), hospitalization charges and length of stay in hospital are available in the NIS.
Institutional Review Board approval and data-user agreement
The present study was exempt of Institutional Review Board approval by the University Hospitals Case Medical Center Institutional Review Board. We completed a data-user agreement with Healthcare Cost and Utilization Project-Agency for Healthcare Research and Quality and obtained the NIS data sets. According to the data-user agreement, individual table cell counts of 10 or lower cannot be presented to preserve patient confidentiality. Consequently, these data were not reported in our study and are represented by the designation DS, for discharge information suppressed.
Case selection
All hospitalizations that had an SCT procedure and developed respiratory failure during the hospitalization were selected for analysis. The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) procedural codes used to identify SCT procedures included BM transplant: not specified (ICD-9-CM procedure code of 41.00), autologous BM transplant without purging (41.01), allogeneic BM transplant with purging (41.02), allogeneic BM transplant without purging (41.03), autologous hematopoietic stem cell transplant without purging (41.04), allogeneic hematopoietic stem cell transplant without purging (41.05), cord blood stem cell transplant (41.06), autologous hematopoietic stem cell transplant with purging (41.07), allogeneic hematopoietic stem cell transplant (41.08) and autologous BM transplant with purging (41.09). The ICD-9-CM diagnosis codes used to identify respiratory failure included acute respiratory failure (ICD-9-CM diagnosis code of 518.81), pulmonary insufficiency (acute respiratory distress, acute respiratory insufficiency or adult respiratory distress syndrome) (518.82), acute on chronic respiratory failure (518.84), respiratory distress or insufficiency (786.09) and respiratory arrest (799.1) ( Table 1) .
Outcome variables
The primary outcome variables of interest in the current study were inhospital mortality, hospitalization charges and hospital length of stay. All hospitalization charges were adjusted to year 2010 US dollar values using the hospital care inflation rates obtained from the Bureau of Labor Statistics. 23 The NIS provides information on disposition status of patient following hospitalization. Following hospitalization, each patient is assigned a disposition status, which includes routine discharge from hospital, transfer to another short-term hospital, transfer to a long-term care facility, discharged against medical advice, discharge to home health care, died in hospital while undergoing treatment and discharged alive, but destination is unknown. In the current study, we used the disposition status variable to assess hospital mortality. In the current study, hospital mortality refers to death in the hospital while undergoing treatment.
Independent variables
The main independent variables of interest were performance of continuous invasive mechanical ventilation and/or noninvasive mechanical ventilation. The ICD-9-CM procedure codes used to identify these procedures during hospitalization were continuous invasive mechanical ventilation-unspecified duration (ICD-9-CM procedure code of 96.70), continuous invasive mechanical ventilation for o 96 h (96.71), continuous invasive mechanical ventilation ⩾ 96 h (96.72) and noninvasive mechanical ventilation (93.90). The demographic variables examined included sex, race, type of admission, insurance status and comorbid burden. The NIS comorbid severity files were used to estimate the comorbid burden. The NIS severity files examine 29 different comorbid conditions including AIDS, alcohol abuse, deficiency anemias, rheumatoid arthritis/collage vascular diseases, chronic blood loss anemia, congestive heart failure, chronic pulmonary disease, coagulopathy, depression, uncomplicated diabetes, diabetes with chronic complications, drug abuse, hypertension, liver disease, lymphoma, fluid and electrolyte disorders, metastatic cancer, neurological disorders, obesity, paralysis, peripheral vascular disorders, psychoses, pulmonary circulation disorders, renal failure, solid tumor without metastasis, peptic ulcer disease excluding bleeding, valvular disease and weight loss. The occurrence of each of these conditions was summed to compute the comorbid burden.
Analytical approach
The association between in-hospital mortality and continuous invasive mechanical ventilation and noninvasive mechanical ventilation was examined by a multivariable logistic regression model. Odds ratios and 95% confidence intervals were computed in the logistic regression model. Multivariable linear regression models were used for hospital charges and length of stay in hospital. As hospitalization charges and length of stay data were skewed, these were log transformed and used as dependent variables in the regression models. The effects of age, sex, race, insurance status, type of transplantation, comorbid burden, year of hospitalization, hospital-teaching status, hospital region and hospital bed size were adjusted in the multivariable regression models. Taylor linearization method was used to fit the regression models. Hospital stratum was used as the stratification variable. The unit of analysis was each individual hospitalization. The effects of clustering of outcomes were adjusted in the regression models. All statistical tests were two-sided and a P-value of o0.05 was deemed to be statistically significant. Statistical analyses were conducted using SAS Version 9.3 (SAS Institute, Cary, NC, USA) and SUDAAN Version 10.0.1 (Research Triangle Institute, Durham, NC, USA) software. Of these 6074 hospitalizations, acute respiratory failure occurred in 4780 hospitalizations, pulmonary insufficiency in 668 hospitalizations, acute on chronic respiratory failure in 109 hospitalizations, respiratory distress/insufficiency in 521 hospitalizations and respiratory arrest in 52 hospitalizations. The characteristics of the study cohort are summarized in A total of 3075 patients died in hospital (50.6% in-hospital mortality rate) ( Table 4 ). The in-hospital mortality rates were 60.6% among those with continuous invasive mechanical ventilation for o96 h, 66.5% among those with continuous invasive mechanical ventilation of ⩾ 96 h, 38.1% among those with both o96 and ⩾ 96 h and 55.1% among those who had noninvasive mechanical ventilation. In-hospital mortality rate among those without continuous invasive mechanical ventilation was 30.5%. The results of the multivariable logistic regression analysis examining the association between types of mechanical ventilation and inhospital mortality are summarized in Table 5 . Following adjustment for effects of age, sex, race, comorbid burden, insurance status, allogeneic transplantation, type of admission, year of hospitalization, teaching status of hospital, bed size and hospital region, those who had continuous invasive mechanical ventilation of o 96 h were associated with an increased odds for in-hospital mortality (odds ratio = 3.42, P o0.0001) compared with those who did not have invasive mechanical ventilation. Those who had continuous invasive mechanical ventilation for ⩾ 96 h were associated with a higher odds for in-hospital mortality (odds ratio = 4.61) compared with those without continuous invasive mechanical ventilation.
RESULTS
During
The overall mean hospitalization charge was $620 765 and the total hospitalization charges for the entire cohort of hospitalizations was $3.34 billion. The mean charges were $484 434 among those with continuous invasive mechanical ventilation of o96 h (total hospitalization charges for this cohort was $490.6 million), $762 515 among those with continuous mechanical ventilation ⩾ 96 h (total hospitalization charges for this cohort was $1.54 billion), $916 415 among those who had continuous invasive mechanical ventilation of both o 96 and ⩾ 96 h duration (total hospitalization charges for this cohort was $44.8 million) and $658 420 among those who had noninvasive mechanical ventilation (total hospitalization charges for this cohort was $235 million) ( Table 4 Table 4 ). The results of the multivariable linear regression analysis examining the association between types of mechanical ventilation and lengths of stay are summarized in Table 7 [17] [18] [19] [20] [24] [25] [26] Current national estimates and resource utilization are unknown. Using the largest all-payer in-patient database in United States, we show that the overall prevalence of acute respiratory distress/failure in all hospitalized stem cell transplant patients is 6%. In addition, a gradual yearly increase in the prevalence of acute respiratory failure in hospitalized stem cell transplant patients was observed. The overall in-hospital mortality rate for hospitalized stem cell transplant patients with acute respiratory failure was 50%. After adjusting for a multitude of patient and hospital level factors, any need for invasive mechanical ventilation in hospitalized stem cell transplant patients with respiratory failure was associated with worse outcomes. Specifically, we show that duration of invasive mechanical ventilation (⩾96 h) is an independent predictor of higher in-hospital mortality.
Factors influencing the in-hospital mortality Prior studies have shown that approximately 40% of BM transplant recipients develop one or more complications that necessitate ICU care, with respiratory failure being the most common cause, 19, 24, 25, 27 and of these at least 25-75% eventually need ventilator support. 19, 20, 26 In addition, prior studies reveal that BM transplant recipients with respiratory distress needing ICU care but not mechanical ventilation have a mortality rate of approximately Outcomes of stem cell transplant patients with respiratory failure V Allareddy et al 20%. In the present study, we report a 30% in-hospital mortality rate for those who did not undergo mechanical ventilation. The higher mortality could be due to factors such as sepsis, GVHD liver failure, cardiac dysfunction, renal insufficiency or other multiorgan dysfunction, or patient's advance directive of a 'do not intubate' or 'do not attempt resuscitation' status. Noninvasive mechanical ventilation (bi-level positive airway pressure or continuous positive airway pressure) is an alternative management strategy for respiratory distress in cancer patients. 14 In one particular study of noninvasive ventilation in oncologic patients, 13 of 23 (57%) patients were successfully supported and discharged alive. 28 In the present study, the mortality rate was 55% for noninvasive mechanical ventilation group; however, when this group was compared with those who did not have noninvasive mechanical ventilation, statistical significance was not reached after adjusting for known confounding factors. The role of early noninvasive mechanical ventilation merits further research.
African Americans and Hispanics were associated with higher odds of in-hospital mortality in our study. The effect of age on mortality was marginal, a 1% increase in risk with each increasing year. Further, gender, type of admission (elective vs emergent), insurance status, year of hospitalization and other hospital characteristics did not influence the in-hospital mortality, probably suggesting that the need for mechanical ventilation is an important predictor of outcomes.
Duration of mechanical ventilation has been considered an uncertain predictor of outcomes. 19, 20, 29, 30 In our study, we show that ⩾ 96 h of invasive mechanical ventilation is associated with the highest odds of in-hospital mortality, hospital charges and length of stay. Prolonged mechanical ventilation (⩾96 h) may suggest severe respiratory failure, the lack of adequate response to conventional ventilator therapy or multifactorial issues that may portend poor outcomes.
In the present study, the type of graft (autologous vs allogeneic) did not influence the mortality. This may suggest that, although GVHD is a risk factor for respiratory failure, it may not predict higher risk of mortality. However, further empirical evidence is needed to support this hypothesis.
Factors influencing length of stay and hospital charges It is known that prolonged mechanical ventilation is associated with longer lengths of stay and hospital costs. 31, 32 In the present study, patients who had o 96 h invasive mechanical ventilation had lower hospital charges and length of stay compared with those who did not receive mechanical ventilation, which can be explained by relatively higher mortality in that group. It is interesting to note that allogeneic recipients with respiratory failure had higher charges and length of stay compared with autologous and cord cell transplant patients. One possible explanation could be the development of complications such as GVHD in this allogeneic population. Elective admissions had expected lower length of stay compared with urgent/emergent admissions, suggesting either lower severity of illness or earlier diagnosis/management of illness. Noninvasive mechanical ventilation did not influence the in-hospital mortality or hospital charges, although it was associated with lower length of stay. Further studies are needed to elicit the impact of noninvasive mechanical ventilation on outcomes in hospitalized stem cell transplant patients with respiratory distress.
Strengths and limitations
To our knowledge, this is the largest cohort of stem cell transplant hospitalizations in whom the prevalence of respiratory distress/ failure was estimated. The nationwide sample is more representative of practices beyond certain single center experiences and hence the results may be more generalizable.
There are limitations to our study. These stem largely from the nature of our study design and use of large secondary hospital discharge data sets. The retrospective nature of the study precludes us from drawing cause and effect relationships; however, the associations shown in this study are consistent with Outcomes of stem cell transplant patients with respiratory failure V Allareddy et al prior single center experiences, and are likely reflective of true outcomes. As in any large administrative data set, billing and coding inaccuracies are possible; nevertheless, more than 1000 publications to date have validated the usefulness of this particular population-based large data set. 22 It is likely that coding practices vary between and within hospitals. Any systematic variations in coding patterns could yield biased estimates. The present study included only hospitalization outcomes. We were Outcomes of stem cell transplant patients with respiratory failure V Allareddy et al unable to examine post-discharge outcomes because of the lack of information on these variables. It would be interesting to examine the impact of duration of mechanical ventilation on immediate and long-term post-discharge outcomes. Lack of availability of these data elements precluded us from examining the same. The hospital charges examined in the present study included only those levied by the hospitals. Certain medication costs, loss of productivity and other indirect costs associated with the hospitalizations were not examined. Consequently, the economic outcomes presented in the current study are likely to be underestimates of the true economic burden associated with these hospitalizations. Information on behavior variables such as Outcomes of stem cell transplant patients with respiratory failure V Allareddy et al dietary habits, smoking history and other pertinent factors was not available in the NIS data set. Consequently, our risk adjustment was limited to the variables present in the data set. Owing to this, we should not discount the possibility of omitted variable bias. In addition, the nature of the data set precluded us from assessing the impact of severity of primary respiratory illness and other organ dysfunction on outcomes (SOFA (sequential organ failure assessment), SAPS (simplified acute physiology score), LOD (logistic organ dysfunction score), PRISM (Pediatric RISk of Mortality), etc.) owing to the lack of certain patient level physiologic and biologic variables. Certain known predictors of outcomes such as time interval from stem cell transplant to admission (o 30 days, ⩾ 30 days) and corticosteroid treatment were not accounted for in this study. Finally, our study looked at all hospitalizations, not individual patients (lack of patient identifiers), and hence readmissions were not identified.
Indications for SCT are expanding, and with an increasing utilization of such services worldwide, there is an increased emphasis on the provision of cost-effective care that is sustainable. Although cost effectiveness of hematopoietic cell transplantation has been described, 33 such perspectives rely on single institution experiences. Identifying the origin of hospital charges in expensive procedures such as SCT is the first step in cost containment. Prior research 34 has shown that SCT patients transferred to the ICU had charges 68% greater than non-ICU patients and those patients who died of transplant-related toxicity before day 100 had hospital charges that were 83% greater than those who survived beyond day 100. The most common cause of medical ICU admission is respiratory distress. In the present study, we describe the economics and outcomes associated with the use of mechanical ventilation in stem cell transplant patients using a large nationalized database. Although the present study reveals that the in-hospital mortality and hospital resource utilization are substantial in this cohort, it provides opportunities for closer examination of medical practices with the aim of reducing inefficiencies while preserving quality of care. The factors that might be contributing to respiratory failure include increased utilization of SCT in patients with multiple comorbidities. Prior research [35] [36] [37] [38] has shown that certain factors such as disease status and comorbidity index may affect non-relapse mortality and survival, and hence may need to be carefully considered. One such example would be assessing the impact of active smoking status (and associated lung conditions such as chronic obstructive pulmonary disease) in patients who are stem cell transplant recipients. Unfortunately, smoking status is not available in the NIS data set, which precludes us from adjusting for this effect in our study and should be the focus in future studies. Identification of factors that predispose to respiratory failure in this population is of paramount importance, especially given the mortality and the economics associated with it. Interestingly, in the present study, consistent with other studies 39, 40 each one unit increase in comorbid burden did not statistically influence the in-hospital mortality, length of stay or hospital charges. The complex relationship between comorbidity and development of respiratory failure in this population merits further research.
Cost-effective approaches would include but not be limited to early diagnosis and aggressive management of any respiratory symptoms; optimal and early utilization of noninvasive mechanical ventilation; evidence-based approach incorporating current proven ventilator strategies, including optimizing pulmonary toileting and patient positioning (for example, prone); early referral to transplantation centers; multidisciplinary approach to patient care; optimizing timing of diagnostic procedures such as bronchoscopies; and comparative effectiveness of various transplantation modalities. Finally, there is a need to better understand the costs associated with long-term follow up of SCT survivors of respiratory distress.
In conclusion, in this large cohort of hospitalized stem cell transplant patients, acute respiratory distress/failure is not an uncommon presentation. Any need for invasive mechanical ventilation was associated with a higher mortality in hospitalized stem cell transplant patients with respiratory failure. Mortality was highest in those needing the invasive mechanical ventilation for ⩾ 96 h. In-hospital resource utilization of mechanically ventilated stem cell transplant patients was significant.
